Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

Daniel Ghinn spotlights how this pharma company is facilitating ... describing it as 'The official Twitter profile for news and information on Novartis-sponsored cancer trials in the US only ...

Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Shares in the company shot up to around $108 million after the rumour of Novartis’ interest in making ... the broad efficacy and encouraging safety profile of aficamten give it a chance of ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...

DAVENPORT & Co LLC reduced its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 3.3% in the fourth quarter, ...